Comparison of selective intra-arterial to standard intravenous administration in percutaneous electrochemotherapy (pECT) for liver tumors
, , , , , , , , , , et
27 févr. 2025
À propos de cet article
Catégorie d'article: research article
Publié en ligne: 27 févr. 2025
Pages: 100 - 109
Reçu: 23 janv. 2025
Accepté: 04 févr. 2025
DOI: https://doi.org/10.2478/raon-2025-0017
Mots clés
© 2025 Tim Wilke et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
FIGURE 1.
FIGURE 2.
Response to percutaneous electrochemotherapy (pECT) treatment in the 2 groups
| RESPONSE | i.v. pECT (N = 21) | i.a. pECT (N = 31) | P value | P value | ||
|---|---|---|---|---|---|---|
| N | % | N | % | Overall distribution | CR |
|
| 13 | 61.9% | 25 | 80.6% | 0.3454 | 0.1349 | |
| 5 | 23.8% | 4 | 12.9% | |||
| 1 | 4.8% | 0 | 0.0% | |||
| 0 | 0.0% | 1 | 3.2% | |||
| 2 | 9.5% | 1 | 3.2% | |||
Descriptive characteristics of the patients in the 2 groups
| PATIENTS | i.v. pECT (N = 18) | i.a. pECT (n = 26) | P value | ||
|---|---|---|---|---|---|
| N | % | N | % | ||
| |
8 | 44% | 15 | 58% | 0.5406 |
| |
10 | 56% | 11 | 42% | |
| |
7 | 39% | 10 | 38% | 0.4620 |
| |
4 | 22% | 4 | 15% | |
| |
2 | 11% | 2 | 8% | |
| |
0 | 0% | 3 | 12% | |
| |
2 | 11% | 0 | 0% | |
| |
1 | 6% | 2 | 8% | |
| |
1 | 6% | 0 | 0% | |
| |
0 | 0% | 1 | 4% | |
| |
0 | 0% | 1 | 4% | |
| |
0 | 0% | 1 | 4% | |
| |
0 | 0% | 1 | 4% | |
| |
0 | 0% | 1 | 4% | |
| |
1 | 6% | 0 | 0% | |
| Synchronous | 8 | 44% | 16 | 62% | 0.5343 |
| Metachronous | 8 | 44% | 8 | 31% | |
| No | 2 | 11% | 2 | 7% | |
| None | 9 | 50% | 17 | 65% | 0.3613 |
| Yes | 9 | 50% | 9 | 35% | |
| Lung | 3 | 17% | 3 | 12% | 0.6025 |
| Bone | 1 | 6% | 2 | 8% | |
| Kidney | 1 | 6% | 1 | 4% | |
| Lung + bone + brain | 1 | 6% | 0 | 0% | |
| Bone + peritoneum | 1 | 6% | 0 | 0% | |
| Pleural + bone | 1 | 6% | 0 | 0% | |
| Retroperineal | 1 | 6% | 0 | 0% | |
| Adrenal gland | 0 | 0% | 1 | 4% | |
| Lymphnode | 0 | 0% | 1 | 4% | |
| Bone + lymphnode | 0 | 0% | 1 | 4% | |
| Systemic therapy | 16 | 89% | 26 | 100% | 0.1617 |
| Liver surgery | 4 | 22% | 12 | 46% | 0.1251 |
| Local treatments | 11 | 61% | 8 | 31% | 0.0657 |
| TACE | 8 | 43% | 4 | 15% | 0.1529 |
| TACE+RFA | 1 | 6% | 0 | 0% | |
| TACE+CP | 1 | 6% | 0 | 0% | |
| TACE/MWA/CRYOTH | 0 | 0% | 2 | 8% | |
| CRYOTH | 1 | 6% | 0 | 0% | |
| IBT | 0 | 0% | 2 | 8% | |
| Cardiac diseases | 6 | 33% | 7 | 27% | 0.7422 |
| Pulmonary diseases | 3 | 17% | 7 | 27% | 0.4889 |
| Liver diseases | 9 | 50% | 0 | 0% | <0.0001 |
| 1 | 15 | 83% | 21 | 81% | 1.000 |
| 2 | 3 | 17% | 5 | 19% | |
Characteristics of target lesions in the 2 groups
| LESIONS | i.v. pECT (N = 21) | i.a. pEC (N = 31) | P value | ||
|---|---|---|---|---|---|
| N | % | N | % | ||
| Hypervascular | 2 | 9.5% | 5 | 16.1% | 0.7664 |
| Intermediate | 14 | 66.7% | 20 | 64.5% | |
| Hypovascular | 5 | 23.8% | 6 | 19.4% | |
| Yes | 19 | 90.5% | 21 | 67.7% | 0.0927 |
| No | 2 | 9.5% | 10 | 32.3% | |
| Distant (> 10 mm) | 4 | 19.0% | 8 | 25.8% | 0.5389 |
| Close (1 mm to 10 mm) | 6 | 28.6% | 5 | 16.1% | |
| Adjacent (< 1 mm) | 11 | 52.4% | 18 | 58.1% | |
| Yes | 7 | 33.3% | 8 | 25.8% | 0.7559 |
| No | 14 | 66.7% | 23 | 74.2% | |
| TACE (transarterial chemoembolization) | 6 | 28.6% | 4 | 12.9% | 0.1474 |
| CP (chemoperfusion) | 1 | 4.8% | 0 | 0.0% | |
| IBT (interstitial brachytherapy) | 0 | 0.0% | 2 | 6.5% | |
| TACE/MWA/CRYOTH | 0 | 0.0% | 2 | 6.5% | |
| Yes | 20 | 95.2% | 31 | 100.0% | 0.2199 |
| No | 1 | 4.8% | 0 | 0.0% | |